Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with the latest pipeline addition, the cytomegalovirus. The company is currently looking to raise 102 MSEK in a rights issue to finance the next step with the ES2B-C001 breast cancer vaccine. CEO Bent U. Frandsen tells us more about the ongoing activities in BioStock Investor Pitch today at 08.45 am.
See ExpreS2ion Biotechnologies CEO Bent U. Frandsen present the company below.
The invitation to persons concerned to subscribe for units in ExpreS2ion Biotechnologies will only take place through the prospectus published on 27 March 2023. The prospectus has been approved and registered by the Financial Supervisory Authority and published on https://expres2ionbio.com/.
